Stay updated on APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page.

Latest updates to the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page
- CheckyesterdayChange DetectedThe page has undergone significant content removal, particularly details about a Phase III clinical study for APL-2 in treating Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD), including inclusion and exclusion criteria. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference21%
- Check8 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check23 days agoNo Change Detected
- Check52 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check66 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
- Check73 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
Stay in the know with updates to APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page.